HK1246790A1 - 乙炔基衍生物 - Google Patents

乙炔基衍生物

Info

Publication number
HK1246790A1
HK1246790A1 HK18106336.0A HK18106336A HK1246790A1 HK 1246790 A1 HK1246790 A1 HK 1246790A1 HK 18106336 A HK18106336 A HK 18106336A HK 1246790 A1 HK1246790 A1 HK 1246790A1
Authority
HK
Hong Kong
Prior art keywords
ethynyl derivatives
ethynyl
derivatives
Prior art date
Application number
HK18106336.0A
Other languages
English (en)
Inventor
喬治‧耶施克
菲奧‧奧哈拉
讓-馬克‧普朗謝
安東尼奧‧里奇
丹尼爾‧呂厄
埃里克‧維埃拉
Original Assignee
豪夫邁．羅氏有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 豪夫邁．羅氏有限公司 filed Critical 豪夫邁．羅氏有限公司
Publication of HK1246790A1 publication Critical patent/HK1246790A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK18106336.0A 2015-08-03 2018-05-16 乙炔基衍生物 HK1246790A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15179550 2015-08-03
PCT/EP2016/068359 WO2017021384A1 (en) 2015-08-03 2016-08-02 Ethynyl derivatives

Publications (1)

Publication Number Publication Date
HK1246790A1 true HK1246790A1 (zh) 2018-09-14

Family

ID=53776452

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18106336.0A HK1246790A1 (zh) 2015-08-03 2018-05-16 乙炔基衍生物

Country Status (21)

Country Link
US (1) US10011607B2 (zh)
EP (1) EP3331882B1 (zh)
JP (1) JP6975511B2 (zh)
KR (1) KR20180030857A (zh)
CN (1) CN107667107B (zh)
AR (1) AR105556A1 (zh)
AU (1) AU2016302696B2 (zh)
BR (1) BR112017023951A2 (zh)
CA (1) CA2983908A1 (zh)
CL (1) CL2018000278A1 (zh)
CO (1) CO2017011010A2 (zh)
HK (1) HK1246790A1 (zh)
IL (1) IL255103B (zh)
MX (1) MX2018001486A (zh)
PE (1) PE20180357A1 (zh)
PH (1) PH12018500247A1 (zh)
RU (1) RU2722014C9 (zh)
TW (1) TWI621619B (zh)
UA (1) UA120888C2 (zh)
WO (1) WO2017021384A1 (zh)
ZA (1) ZA201707015B (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10865191B2 (en) 2015-08-03 2020-12-15 Bristol-Myers Squibb Company Heterocyclic compounds useful as modulators of TNF alpha
NZ739228A (en) 2015-08-03 2019-11-29 Glenmark Pharmaceuticals Sa Novel compounds as ror gamma modulators
GB201513742D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012005248A (es) * 2009-11-06 2012-06-14 Univ Vanderbilt Aril- y heteroaril-sulfonas como potenciadores alostericos de mglur4, composiciones y metodos de tratamiento de la disfuncion neurologica.
US8420661B2 (en) * 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
UA113625C2 (xx) * 2011-04-26 2017-02-27 Похідні піразолідин-3-ону
AU2014327504B2 (en) * 2013-09-25 2018-01-04 F. Hoffmann-La Roche Ag Ethynyl derivatives
TWI649310B (zh) * 2014-01-10 2019-02-01 赫孚孟拉羅股份公司 乙炔基衍生物
JP6286577B2 (ja) * 2014-02-25 2018-02-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ エチニル誘導体

Also Published As

Publication number Publication date
RU2018105872A3 (zh) 2019-12-26
TWI621619B (zh) 2018-04-21
RU2018105872A (ru) 2019-09-05
PE20180357A1 (es) 2018-02-21
PH12018500247A1 (en) 2018-08-13
EP3331882B1 (en) 2020-04-29
MX2018001486A (es) 2018-03-15
CN107667107B (zh) 2021-05-18
CO2017011010A2 (es) 2018-02-09
WO2017021384A1 (en) 2017-02-09
AR105556A1 (es) 2017-10-18
AU2016302696A1 (en) 2017-11-02
KR20180030857A (ko) 2018-03-26
BR112017023951A2 (pt) 2018-07-24
TW201718589A (zh) 2017-06-01
CN107667107A (zh) 2018-02-06
UA120888C2 (uk) 2020-02-25
AU2016302696B2 (en) 2020-05-07
JP6975511B2 (ja) 2021-12-01
CA2983908A1 (en) 2017-02-09
EP3331882A1 (en) 2018-06-13
CL2018000278A1 (es) 2018-07-06
ZA201707015B (en) 2018-11-28
RU2722014C9 (ru) 2020-10-22
US10011607B2 (en) 2018-07-03
IL255103A0 (en) 2017-12-31
JP2018522037A (ja) 2018-08-09
RU2722014C2 (ru) 2020-05-26
IL255103B (en) 2020-01-30
US20180127429A1 (en) 2018-05-10

Similar Documents

Publication Publication Date Title
HK1255045A1 (zh) 取代的氧代吡啶衍生物
IL253381B (en) History of h9–pyrrolo–dipyridine
HK1245258A1 (zh) 新的二氟酮酰胺衍生物
HRP20182016T1 (hr) Derivati etinila
IL248773A0 (en) History of naphthyridinedione
IL251005B (en) Pyrido-oxazinone derivatives
ZA201900113B (en) Ethynyl derivatives
HK1246790A1 (zh) 乙炔基衍生物
HK1259107A1 (zh) 氨基唑衍生物
PT3228616T (pt) Derivados de piridina
HK1249096A1 (zh) 乙炔基衍生物